VelocImmune technology

E579613

Regeneron proprietary technology antibody discovery platform biotechnology platform

VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (6)

Label	Occurrences
Regeneron VelocImmune platform	1
Regeneron’s VelocImmune platform	1
Regeneron’s VelociMouse technology	1
Regeneron’s VelociSuite antibody discovery technologies	1
VelocImmune antibody technology	1
VelocImmune technology canonical	1

How this entity was disambiguated

This entity first appeared as the object of triple T6251195 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: VelocImmune technology
Context triple: [Regeneron Pharmaceuticals, knownFor, VelocImmune technology]

A. Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
B. Immunix
Immunix was a security-focused software company known for developing Linux security technologies, including the precursor to the AppArmor mandatory access control system.
C. StaR technology
StaR technology is a proprietary platform developed by Heptares Therapeutics for stabilizing G protein–coupled receptors (GPCRs) to enable their detailed structural analysis and use in structure-based drug discovery.
D. Bicycle Therapeutics
Bicycle Therapeutics is a biotechnology company that develops novel therapeutics based on its proprietary bicyclic peptide (Bicycle®) platform, with a focus on targeted treatments for cancer and other serious diseases.
E. human adenovirus serotype 26 (Ad26)
Human adenovirus serotype 26 (Ad26) is a non-replicating viral vector commonly used in vaccine development to deliver genetic material encoding target antigens and stimulate an immune response.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: VelocImmune technology
Target entity description: VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.

A. Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
B. Immunix
Immunix was a security-focused software company known for developing Linux security technologies, including the precursor to the AppArmor mandatory access control system.
C. StaR technology
StaR technology is a proprietary platform developed by Heptares Therapeutics for stabilizing G protein–coupled receptors (GPCRs) to enable their detailed structural analysis and use in structure-based drug discovery.
D. Bicycle Therapeutics
Bicycle Therapeutics is a biotechnology company that develops novel therapeutics based on its proprietary bicyclic peptide (Bicycle®) platform, with a focus on targeted treatments for cancer and other serious diseases.
E. human adenovirus serotype 26 (Ad26)
Human adenovirus serotype 26 (Ad26) is a non-replicating viral vector commonly used in vaccine development to deliver genetic material encoding target antigens and stimulate an immune response.
F. None of above. chosen

Statements (39)

Predicate	Object
instanceOf	Regeneron proprietary technology ⓘ antibody discovery platform ⓘ biotechnology platform ⓘ
advantage	high diversity of antibody repertoires ⓘ reduced risk of immunogenicity compared with chimeric antibodies ⓘ shortened timelines for antibody discovery ⓘ
appliedIn	immunology drug development ⓘ infectious disease therapeutics ⓘ oncology drug development ⓘ rare disease therapeutics ⓘ
basedOn	genetically engineered mice ⓘ
commercialUse	internal Regeneron drug pipeline ⓘ strategic collaborations with other pharmaceutical companies ⓘ
componentOf	Regeneron antibody discovery and development platform ⓘ linked to: Regeneron Pharmaceuticals
developer	Regeneron Pharmaceuticals ⓘ
enables	in vivo affinity maturation ⓘ rapid antibody generation ⓘ
field	biopharmaceuticals ⓘ immunology ⓘ therapeutic antibody engineering ⓘ
hasKeyFeature	human immunoglobulin gene loci inserted into mouse genome ⓘ inactivation of mouse immunoglobulin genes ⓘ
intellectualPropertyStatus	patented technology ⓘ
notableProductAssociation	REGN-COV2 antibody cocktail ⓘ linked to: REGN-COV2 dupilumab ⓘ linked to: Dupixent other Regeneron monoclonal antibody therapeutics ⓘ
owner	Regeneron Pharmaceuticals ⓘ
produces	fully human monoclonal antibodies ⓘ
relatedTo	Regeneron VelociSuite ⓘ linked to: Regeneron Pharmaceuticals VelociGene ⓘ VelociMouse ⓘ
supports	clinical candidate selection ⓘ generation of antibody combinations ⓘ
technologyType	in vivo antibody discovery system ⓘ transgenic animal platform ⓘ
usedFor	generation of fully human monoclonal antibodies ⓘ preclinical drug development ⓘ therapeutic antibody discovery ⓘ
usesOrganism	transgenic mice ⓘ

How these facts were elicited